

Patent Application No. 10/668,633  
Attorney Docket No. PC111089C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**  
**CENTRAL FAX CENTER**

MAY 04 2005

IN RE APPLICATION OF: :  
Kimberly O. Cameron, et al.

Examiner: Golam M. Shameem

APPLICATION NO.: 10/668,633 :

Group Art Unit: 1626

FILING DATE: September 23, 2003 :

TITLE: EP4 Receptor Selective Agonists in the :  
Treatment of Osteoporosis

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. §1.321 (c)

The owner, Pfizer, Inc, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full and complete statutory term prior patent Nos. 6,552,067 and 6,747,054 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, including any term extensions thereto authorized or which may be authorized by law, and as the term of said prior patents is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patents are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full and complete statutory term as defined in 35 U.S.C. 154 and 173, including any term extensions thereto authorized or which may be authorized by law, of the prior patents, "as the term of said prior patents is presently shortened by any terminal disclaimer," in the event that said prior patents later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

05/06/2005 NGUYEN1 00000032 161445 10668633

01 FC:1814 130.00 DA

Patent Application No. 10/668,633  
Attorney Docket No. PC111089C


The undersigned hereby declares that all statements made herein of his own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned is the attorney of record in the instant application.

Please charge the \$130.00 fee due under 37 C.F.R. §§ 1.321(b)(4) and 1.20(d) to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Respectfully submitted,

Date: May 4, 2005  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, CT 06340  
(860) 686-2372

  
Lyman H. Smith  
Attorney for Applicant(s)  
Reg. No. 44,342

82192